U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C45H73NO16
Molecular Weight 884.0582
Optical Activity UNSPECIFIED
Defined Stereocenters 16 / 16
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JOSAMYCIN PROPIONATE

SMILES

[H][C@@]2(O[C@H]1[C@@H](CC=O)C[C@@H](C)[C@@H](OC(=O)CC)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(C)=O)[C@@H]1OC)O[C@H](C)[C@@]([H])(O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C

InChI

InChIKey=NVBREHSOJSEKBQ-ZQMZUEOGSA-N
InChI=1S/C45H73NO16/c1-13-34(49)59-32-18-16-14-15-17-27(5)55-36(51)23-33(58-30(8)48)42(54-12)41(31(19-20-47)22-26(32)4)62-44-39(52)38(46(10)11)40(28(6)57-44)61-37-24-45(9,53)43(29(7)56-37)60-35(50)21-25(2)3/h14-16,18,20,25-29,31-33,37-44,52-53H,13,17,19,21-24H2,1-12H3/b15-14+,18-16+/t26-,27-,28-,29+,31+,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1

HIDE SMILES / InChI
Molecular Formula C45H73NO16
Molecular Weight 884.0582
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 16 / 16
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Josamycin propionate, a tasteless josamycin derivative suitable for the preparation of pediatric oral suspension. After oral administration Josamycin propionate underwent metabolic transformation to Josamycin, semi-synthetic 16-membered ring macrolide, that acts via protein synthesis inhibition.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.5 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Not Provided
504
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Application of liquid chromatography-ion trap mass spectrometry to the characterization of the 16-membered ring macrolide josamycin propionate.
2004 Apr
Patents

Patents

DE2230729
1

Sample Use Guides

In Vivo Use Guide
The mean daily dose of josamycin was 53.5 mg/kg (as Josamycin propionate) and the drug was administered for an average of 7.31 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:20:38 GMT 2023
Edited
by admin
on Fri Dec 15 18:20:38 GMT 2023
Record UNII
053VA4B06Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
JOSAMYCIN PROPIONATE
MART.   MI   WHO-DD  
Common Name English
JOSACINE
Brand Name English
JOSAMYCIN PROPIONATE [EP MONOGRAPH]
Common Name English
9-PROPIONYLJOSAMYCIN
Common Name English
LEUCOMYCIN A3 PROPIONATE
Common Name English
KITASAMYCIN A3 PROPIONATE
Common Name English
JOSAMY
Brand Name English
JOSAXIN
Common Name English
LEUCOMYCIN V 3-ACETATE 9-PROPANOATE 4''-(3-METHYLBUTANOATE)
Common Name English
JOSAMYCIN PROPIONATE [MART.]
Common Name English
Josamycin propionate [WHO-DD]
Common Name English
JOSAMYCIN PROPIONATE [JAN]
Common Name English
LEUCOMYCIN V, 3-ACETATE 4B-(3-METHYLBUTANOATE) 9-PROPANOATE
Common Name English
JOSAMYCIN PROPIONATE [MI]
Common Name English
TURIMYCIN A5 PROPIONATE
Common Name English
WILPRAFEN
Brand Name English
Code System Code Type Description
CAS
56111-35-4
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
SUPERSEDED
MESH
C043427
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
RXCUI
28069
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m6585
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL224436
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
EVMPD
SUB02814MIG
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
FDA UNII
053VA4B06Y
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
CAS
57078-36-1
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
SUPERSEDED
CAS
83310-75-2
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
SUPERSEDED
CAS
51016-68-3
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
NON-SPECIFIC SUBSTITUTION
EPA CompTox
DTXSID701023454
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
CAS
40922-77-8
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
CAS
189631-89-8
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
SUPERSEDED
ECHA (EC/EINECS)
255-140-7
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
PUBCHEM
23724981
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
SMS_ID
100000084908
Created by admin on Fri Dec 15 18:20:38 GMT 2023 , Edited by admin on Fri Dec 15 18:20:38 GMT 2023
PRIMARY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966